Growth Momentum PolyNovo has demonstrated rapid revenue expansion from $13.7M in FY19 to approximately $150M in FY26, indicating strong market demand and a scalable sales model. This growth trajectory suggests opportunities to upsell expanded indications and geographic expansion, particularly in new markets and hospital systems prioritizing advanced wound care solutions.

Global Footprint With experience treating 106,000+ patients across 46 countries, PolyNovo operates internationally and seeks to expand into additional regions. Sales teams can target large multi-site healthcare providers and regional distributors in new territories, leveraging existing distribution rights and potential partnerships for SUPRATHEL and related products.

Strategic Partnerships Past collaborations, including the DeepView System evaluation for burn indication and exclusive rights for SUPRATHEL in key regions, indicate a pattern of forming strategic alliances. Business development opportunities exist to pursue co-development, distribution agreements, and integration with AI-driven diagnostics to enhance wound management workflows.

Product Expansion The company plans growth through new products and indications, suggesting sales opportunities across additional wound care solutions and tissue engineering technologies. Reps should map adjacent needs in acute and chronic wound care pipelines and position PolyNovo as a multi-indication partner to hospital systems.

Public Funding & Talent Recent government funding and investments in R&D, plus leadership changes in finance, highlight ongoing commitment to innovation and organizational readiness for scale. Opportunities exist to present value through funded pilots, grant-aligned demonstrations, and collaborations with research centers to accelerate adoption in large clinical networks.